ABT:NYE-Abbott Laboratories

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing Price

USD 58.44

Change

-0.40 (-0.68)%

Market Cap

USD 101.72B

Volume

7.18M

Yahoo Analyst Target

USD 61.88 (5.89%)

STA Analyst Target

USD 59.95 (2.58%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Abbott Laboratories discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the United States.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-01-16 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
JNJ Johnson & Johnson

+1.10 (+0.75%)

USD 394.54B
PFE Pfizer Inc.

+0.06 (+0.16%)

USD 218.16B
NVS Novartis AG

+0.08 (+0.09%)

USD 203.20B
MRK Merck & Company Inc. (new)

+3.41 (+5.81%)

USD 169.11B
ABBV AbbVie Inc.

+2.15 (+2.14%)

USD 163.62B
SNY Sanofi American Depositary Sha..

+0.13 (+0.29%)

USD 113.03B
BMY Bristol-Myers Squibb Company

-2.89 (-4.60%)

USD 98.07B
GSK GlaxoSmithKline PLC

+0.42 (+1.12%)

USD 94.00B
LLY Eli Lilly and Company

-1.69 (-1.94%)

USD 93.91B
AZN Astrazeneca PLC

-0.66 (-1.85%)

USD 88.61B

ETFs Containing ABT

IHI iShares U.S. Medical Devi.. 9.19 % 0.44 %

-0.58 (-1.05%)

USD 1.58B
FTXH First Trust Nasdaq Pharma.. 7.85 % 0.60 %

-0.24 (-1.05%)

USD 2.22M
PJP PowerShares Dynamic Pharm.. 4.93 % 0.56 %

-0.32 (-1.05%)

USD 0.66B
PWB PowerShares Dynamic Large.. 3.36 % 0.57 %

-0.13 (-1.05%)

USD 0.56B
IYH iShares U.S. Healthcare 3.00 % 0.44 %

+0.62 (+-1.05%)

USD 2.04B
FHLC Fidelity MSCI Health Care.. 2.71 % 0.08 %

+0.09 (+-1.05%)

USD 0.97B
VHT Vanguard Health Care 2.62 % 0.10 %

+0.25 (+-1.05%)

USD 7.51B
XLV SPDR Select Sector Fund -.. 2.59 % 0.14 %

+0.43 (+-1.05%)

USD 17.56B
VIG Vanguard Div Appreciation 2.51 % 0.08 %

-0.46 (-1.05%)

USD 28.30B
PILL Direxion Daily Pharmaceut.. 1.78 % 0.00 %

-0.33 (-1.05%)

USD 3.19M

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.40% 26% F 55% F
Dividend Return 0.49% 33% F 45% F
Total Return 2.89% 35% F 59% F
Trailing 12 Months  
Capital Gain 42.78% 83% B 90% A-
Dividend Return 2.63% 41% F 41% F
Total Return 45.41% 83% B 90% A-
Trailing 5 Years  
Capital Gain 78.72% 72% C- 76% C
Dividend Return 14.19% 33% F 43% F
Total Return 92.91% 67% D+ 76% C
Average Annual (5 Year Horizon)  
Capital Gain 9.39% 65% D 72% C-
Dividend Return 11.69% 65% D 72% C-
Total Return 2.30% 35% F 44% F
Risk Return Profile  
Volatility (Standard Deviation) 16.48% 70% C- 46% F
Risk Adjusted Return 70.94% 74% C 62% D-
Market Capitalization 56.45B 73% C 98% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 43.70 17% F 13% F
Price/Book Ratio 3.22 52% F 30% F
Price / Cash Flow Ratio 5.45 30% F 19% F
Price/Free Cash Flow Ratio 24.55 35% F 27% F
Management Effectiveness  
Return on Equity 7.28% 26% F 45% F
Return on Invested Capital 3.83% 35% F 29% F
Return on Assets 3.15% 35% F 56% F
Debt to Equity Ratio 83.50% 41% F 47% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.